Robert Gagnon, MD
Family Medicine · Lakeville, MANPI 1124090493
Payments from drug & device makers
Across 202 payments — averaging $21.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$604
- Pfizer$530
- Lilly USA, LLC$328
- Johnson & Johnson$277
- Novo Nordisk$216
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $1,132 |
| Boehringer Ingelheim | 26 | $604 |
| Pfizer | 30 | $530 |
| Lilly USA, LLC | 18 | $328 |
| Johnson & Johnson | 13 | $277 |
| Novo Nordisk | 12 | $216 |
| AbbVie(2 entities) | 9 | $204 |
| Exact Sciences | 7 | $177 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $170 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $126 |
| Kowa Pharmaceuticals America, Inc. | 4 | $70 |
| GSK | 3 | $65 |
| Abbott | 3 | $61 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $50 |
| Boston Scientific | 2 | $49 |
| Astellas Pharma US Inc | 2 | $45 |
| Mylan Specialty L.p. | 2 | $35 |
| Bayer | 2 | $32 |
| Seqirus USA Inc | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Lucid Diagnostics Inc. | 1 | $20 |
| Eisai Inc. | 1 | $20 |
| Verona Pharma, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$120
How this compares
$4,402 in reported general payments places this provider in the 90th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $84,844 |
| JardianceEmpagliflozin | 52 | $75,353 |
| XareltoRivaroxaban | 57 | $74,171 |
| OzempicSemaglutide | 26 | $33,380 |
| TrulicityDulaglutide | 13 | $26,746 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $22,563 |
| LinzessLinaclotide | 23 | $21,098 |
| OxycontinOxycodone Hcl | 11 | $17,776 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $17,597 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $14,393 |
| MyrbetriqMirabegron | 22 | $11,342 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $10,701 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $10,437 |
| Spiriva RespimatTiotropium Bromide | 11 | $8,060 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $7,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $604 | $101,01077 claims |
| PfizerEliquis | $530 | $84,84459 claims |
| Johnson & JohnsonXarelto | $277 | $74,17157 claims |
| Novo NordiskOzempic | $216 | $33,38026 claims |
| Lilly USA, LLCTrulicity | $328 | $26,74613 claims |
| AbbVieLinzess | $204 | $21,09823 claims |
| Astellas Pharma US IncMyrbetriq | $45 | $11,34222 claims |
| GSKIncruse Ellipta | $65 | $10,70112 claims |
| AstraZenecaSymbicort | $1,132 | $7,10718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Lakeville
- Robert BeckWestford$2.1M
- Katherine Gergen BarnettBoston$226K
- Peter O'DwyerBoston$163K
- Kelly LannuttiWeymouth$122K
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.